NF-κ B promotes leaky expression of adenovirus genes in a replication-incompetent adenovirus vector

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Machitani, M ^a   Sakurai, F ^a   Wakabayashi, K ^a   Nakatani, K ^a   Shimizu, K ^a,b   Tachibana, M ^a   Mizuguchi, H ^a,c,d  

^a OSAKA UNIVERSITY   (Japan)

^b OSAKA OHTANI UNIVERSITY   (Japan)

^c NATIONAL INSTITUTE OF BIOMEDICAL INNOVATION   (Japan)

^d OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN BINDING; VIRAL PROTEIN;

ADENOVIRIDAE; ANIMAL; BINDING SITE; CELL LINE; DRUG EFFECTS; FEMALE; GENE DELETION; GENE EXPRESSION REGULATION; GENE VECTOR; GENETICS; HUMAN; KNOCKOUT MOUSE; LIVER; METABOLISM; MOUSE; PROMOTER REGION; TRANSCRIPTION INITIATION; VIROLOGY; VIRUS REPLICATION;

ADENOVIRIDAE; ADENOVIRUS E2 PROTEINS; ANIMALS; BINDING SITES; CELL LINE; FEMALE; GENE EXPRESSION REGULATION, VIRAL; GENETIC VECTORS; HUMANS; INTERFERON-ALPHA; LIVER; MICE; MICE, KNOCKOUT; NF-KAPPA B; PROMOTER REGIONS, GENETIC; PROTEIN BINDING; SEQUENCE DELETION; TRANSCRIPTIONAL ACTIVATION; VIRUS REPLICATION;

EID: 84955475725     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep19922     Document Type: Article

References (37)

1. Volpers, C. & Kochanek, S. Adenoviral vectors for gene transfer and therapy. J Gene Med 6, S164-171 (2004).
2. McConnell, M. J. & Imperiale, M. J. Biology of adenovirus and its use as a vector for gene therapy. Hum Gene Ther 15, 1022-1033 (2004).
3. Dedieu, J. F. et al. Long-term gene delivery into the livers of immunocompetent mice with E1/E4-defective adenoviruses. J Virol 71, 4626-4637 (1997).
4. Lusky, M. et al. In vitro and in vivo biology of recombinant adenovirus vectors with E1, E1/E2A, or E1/E4 deleted. J Virol 72, 2022-2032 (1998).
5. Shimizu, K., Sakurai, F., Machitani, M., Katayama, K. & Mizuguchi, H. Quantitative analysis of the leaky expression of adenovirus genes in cells transduced with a replication-incompetent adenovirus vector. Mol Pharm 8, 1430-1435 (2011).
6. Wakabayashi, K. et al. Quantitative analysis of virus-Associated RNAI expression following transduction with a replicationincompetent adenovirus vector in vitro and in vivo. J Mol Genet Med 9, 1000169 (2015).
7. Yang, Y. et al. Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy. Proc Natl Acad Sci USA 91, 4407-4411 (1994).
8. Gao, G. P., Yang, Y. & Wilson, J. M. Biology of adenovirus vectors with E1 and E4 deletions for liver-directed gene therapy. J Virol 70, 8934-8943 (1996).
9. Shimizu, K. et al. Suppression of leaky expression of adenovirus genes by insertion of microRNA-targeted sequences in the replication-incompetent adenovirus vector genome. Mol Ther Methods Clin Dev 1, 14035 (2014).
10. Zhou, H., O'Neal, W., Morral, N. & Beaudet, A. L. Development of a complementing cell line and a system for construction of adenovirus vectors with E1 and E2a deleted. J Virol 70, 7030-7038 (1996).
11. Reddy, P. S. et al. Sustained human factor VIII expression in hemophilia A mice following systemic delivery of a gutless adenoviral vector. Mol Ther 5, 63-73 (2002).
12. Mian, A. et al. Toxicity and adaptive immune response to intracellular transgenes delivered by helper-dependent vs. first generation adenoviral vectors. Mol Genet Metab 84, 278-288 (2005).
13. Machitani, M. et al. Improving adenovirus vector-mediated RNAi efficiency by lacking the expression of virus-Associated RNAs. Virus Res 178, 357-363 (2013).
14. Sakurai, H., Kawabata, K., Sakurai, F., Nakagawa, S. & Mizuguchi, H. Innate immune response induced by gene delivery vectors. Int J Pharm 354, 9-15 (2008).
15. Chen, D., Murphy, B., Sung, R. & Bromberg, J. S. Adaptive and innate immune responses to gene transfer vectors: role of cytokines and chemokines in vector function. Gene Ther 10, 991-998 (2003).
16. Hiscott, J., Kwon, H. & Genin, P. Hostile takeovers: viral appropriation of the NF-kappaB pathway. J Clin Invest 107, 143-151 (2001).
17. Shinkai, Y. et al. RAG-2-deficient mice lack mature lymphocytes owing to inability to initiate V(D)J rearrangement. Cell 68, 855-867 (1992).
18. Cao, X. et al. Defective lymphoid development in mice lacking expression of the common cytokine receptor gamma chain. Immunity 2, 223-238 (1995).
19. Suzuki, T. et al. miR-122a-regulated expression of a suicide gene prevents hepatotoxicity without altering antitumor effects in suicide gene therapy. Mol Ther 16, 1719-1726 (2008).
20. Sakurai, F., Kawabata, K., Yamaguchi, T., Hayakawa, T. & Mizuguchi, H. Optimization of adenovirus serotype 35 vectors for efficient transduction in human hematopoietic progenitors: comparison of promoter activities. Gene Ther 12, 1424-1433 (2005).
21. Machitani, M. et al. Development of an adenovirus vector lacking the expression of virus-Associated RNAs. J Control Release 154, 285-289 (2011).
22. Mizuguchi, H. & Kay, M. A. Efficient construction of a recombinant adenovirus vector by an improved in vitro ligation method. Hum Gene Ther 9, 2577-2583 (1998).
23. Mizuguchi, H. & Kay, M. A. A simple method for constructing E1-And E1/E4-deleted recombinant adenoviral vectors. Hum Gene Ther 10, 2013-2017 (1999).
24. Kawabata, K., Sakurai, F., Yamaguchi, T., Hayakawa, T. & Mizuguchi, H. Efficient gene transfer into mouse embryonic stem cells with adenovirus vectors. Mol Ther 12, 547-554 (2005).
25. Matsui, H. et al. A targeted adenovirus vector displaying a human fibronectin type III domain-based monobody in a fiber protein. Biomaterials 34, 4191-4201 (2013).
26. Lieber, A. et al. Inhibition of NF-kappaB activation in combination with bcl-2 expression allows for persistence of first-generation adenovirus vectors in the mouse liver. J Virol 72, 9267-9277 (1998).
27. Zhang, Y. et al. Acute cytokine response to systemic adenoviral vectors in mice is mediated by dendritic cells and macrophages. Mol Ther 3, 697-707 (2001).
28. Yurochko, A. D., Mayo, M. W., Poma, E. E., Baldwin, A. S., Jr. & Huang, E. S. Induction of the transcription factor Sp1 during human cytomegalovirus infection mediates upregulation of the p65 and p105/p50 NF-kappaB promoters. J Virol 71, 4638-4648 (1997).
29. Patel, A. et al. Herpes simplex type 1 induction of persistent NF-kappa B nuclear translocation increases the efficiency of virus replication. Virology 247, 212-222 (1998).
30. Gregory, D., Hargett, D., Holmes, D., Money, E. & Bachenheimer, S. L. Efficient replication by herpes simplex virus type 1 involves activation of the IkappaB kinase-IkappaB-p65 pathway. J Virol 78, 13582-13590 (2004).
31. Shurman, L., Sen, R. & Bergman, Y. Adenovirus E1A products activate the Ig k-chain enhancer in fibroblasts. A possible involvement of the NF-kB binding site. J Immunol 143, 3806-3812 (1989).
32. Pahl, H. L., Sester, M., Burgert, H. G. & Baeuerle, P. A. Activation of transcription factor NF-kappaB by the adenovirus E3/19K protein requires its ER retention. J Cell Biol 132, 511-522 (1996).
33. Gribaudo, G. et al. Interferon-Alpha inhibits the murine cytomegalovirus immediate-early gene expression by down-regulating NFkappa B activity. Virology 211, 251-260 (1995).
34. Engelhardt, J. F., Ye, X., Doranz, B. & Wilson, J. M. Ablation of E2A in recombinant adenoviruses improves transgene persistence and decreases inflammatory response in mouse liver. Proc Natl Acad Sci USA 91, 6196-6200 (1994).
35. Ilan, Y. et al. Transient immunosuppression with FK506 permits long-term expression of therapeutic genes introduced into the liver using recombinant adenoviruses in the rat. Hepatology 26, 949-956 (1997).
36. Iimuro, Y. et al. NFkappaB prevents apoptosis and liver dysfunction during liver regeneration. J Clin Invest 101, 802-811 (1998).
37. Luo, J. L., Kamata, H. & Karin, M. IKK/NF-kappaB signaling: balancing life and death-A new approach to cancer therapy. J Clin Invest 115, 2625-2632 (2005).